• 1
    Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza-Mataftsi E. Influenza A (H5N1): an overview of the current situation. Eurosurveillance 2009; 145:220226.
  • 2
    World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 6 May 2010. Global alert and response (GAR). Available at (Accessed 26 July 2011).
  • 3
    World Health Organization (WHO). Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for the development of candidate vaccine viruses for pandemic preparedness, February 2011. Available at (Accessed 23 May 2011).
  • 4
    Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on Avian Influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261273.
  • 5
    European Committee for Proprietary Medicinal Products (CHMP). Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products, January 24, 2007.
  • 6
    US Food and Drug Administration (FDA) Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration May 2007. Available at (Accessed 10 March 2011).
  • 7
    World Health Organization (WHO). Options for the Use of Human H5N1 Influenza Vaccines and the WHO H5N1 Vaccine Stockpile. Geneva, Switzerland: WHO scientific consultation, 2007.
  • 8
    Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6:458460.
  • 9
    World Health Organization. Pandemic (H1N1) 2009 briefing note 2. Global alert and response (GAR). July 13, 2009. Available at (Accessed 16 March 2011).
  • 10
    Chu DW-S, Hwang SJ, Lim FS et al. Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009; 27:74287435.
  • 11
    Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580589.
  • 12
    Leroux-Roels I, Bernhard R, Gerard P, Dramé M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008; 3:e1665. 499. Doi: 10.1371/journal.pone.0001665.
  • 13
    Rümke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:23782388.
  • 14
    Schwarz TF, Horacek T, Knuf M et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:62846290.
  • 15
    Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:9195.
  • 16
    Reed LT, Muench H. A simple method of calculating fifty percent end point. Am J Hyg 1938; 27:493498.
  • 17
    Moris P, van der Most R, Leroux-roels I et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443454.
  • 18
    Malherbe L, Mark L, Fazilleau N, Heyzer-Williams LJ, Heyzer-Williams MG. Vaccine adjuvants alter TCR-based selection thresholds. Immunity 2008; 28:698709.
  • 19
    Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3:85ra48.